Castle Biosciences (CSTL) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CSTL Stock Forecast

Castle Biosciences stock forecast is as follows: an average price target of $40.50 (represents a 45.16% upside from CSTL’s last price of $27.90) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

CSTL Price Target

The average price target for Castle Biosciences (CSTL) is $40.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $36.00. This represents a potential 45.16% upside from CSTL's last price of $27.90.

CSTL Analyst Ratings

Buy

According to 4 Wall Street analysts, Castle Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CSTL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Castle Biosciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 05, 2024	Sung Ji Nam	BTIG	$45.00	$31.15	44.46%	61.29%
Nov 05, 2024	Catherine Schulte	Robert W. Baird	$39.00	$32.80	18.92%	39.78%
Nov 05, 2024	Paul Knight	KeyBanc	$36.00	$32.80	9.77%	29.03%
Oct 29, 2024	Kyle Mikson	Canaccord Genuity	$42.00	$32.40	29.63%	50.54%
Oct 14, 2024	Sung Ji Nam	BTIG	$40.00	$31.31	27.75%	43.37%
Aug 06, 2024	Sung Ji Nam	BTIG	$35.00	$26.24	33.38%	25.45%
Nov 04, 2022	Catherine Schulte Analyst	Robert W. Baird	$41.00	$24.72	65.86%	46.95%

Row per page

Go to

The latest Castle Biosciences stock forecast, released on Nov 05, 2024 by Sung Ji Nam from BTIG, set a price target of $45.00, which represents a 44.46% increase from the stock price at the time of the forecast ($31.15), and a 61.29% increase from CSTL last price ($27.90).

Castle Biosciences Price Target by Period

	1M	3M	12M
# Anlaysts	4	5	6
Avg Price Target	$40.50	$40.40	$39.50
Last Closing Price	$27.90	$27.90	$27.90
Upside/Downside	45.16%	44.80%	41.58%

In the current month, the average price target of Castle Biosciences stock is $40.50, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 45.16% increase as opposed to Castle Biosciences's last price of $27.90. This month's average price target is up 0.25% compared to last quarter, and up 2.53% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 05, 2024	KeyBanc	Overweight	Overweight	Hold
Oct 29, 2024	Stephens	Buy	Buy	Hold
Oct 29, 2024	Canaccord Genuity	Underperform	Underperform	Hold
Oct 29, 2024	Canaccord Genuity	Buy	Buy	Hold
Oct 14, 2024	BTIG	Buy	Buy	Hold
Aug 06, 2024	BTIG	Buy	Buy	Hold
May 03, 2024	Lake Street	Buy	Buy	Hold
Jun 15, 2023	BTIG	Buy	Buy	Hold
Jun 06, 2023	Canaccord Genuity	Buy	Buy	Hold
Jan 05, 2023	Scotiabank	-	Sector Outperform	Initialise

Row per page

Go to

Castle Biosciences's last stock rating was published by KeyBanc on Nov 05, 2024. The company gave CSTL a "Overweight" rating, the same as its previous rate.

Castle Biosciences Financial Forecast

Castle Biosciences Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$66.12M	$61.49M	$50.14M	$42.04M	$38.34M	$37.01M	$34.84M	$26.85M	$25.04M	$23.48M	$22.76M	$22.81M	$17.30M	$15.22M	$12.71M	$17.42M	$17.63M	$14.77M
Avg Forecast	$72.82M	$72.66M	$71.56M	$62.95M	$68.85M	$68.37M	$67.10M	$59.86M	$80.54M	$79.85M	$69.37M	$66.55M	$56.28M	$48.57M	$44.19M	$37.41M	$37.12M	$34.76M	$28.37M	$25.23M	$23.74M	$22.97M	$19.11M	$16.72M	$15.74M	$15.00M	$8.80M	$13.72M	$11.74M	$9.45M
High Forecast	$75.74M	$75.58M	$74.43M	$65.48M	$71.62M	$71.11M	$69.80M	$62.27M	$83.78M	$80.31M	$69.37M	$66.72M	$61.77M	$48.57M	$45.97M	$38.91M	$38.61M	$34.76M	$28.37M	$25.23M	$23.74M	$22.97M	$19.11M	$16.72M	$15.74M	$15.00M	$8.80M	$13.72M	$11.74M	$9.45M
Low Forecast	$70.60M	$70.44M	$69.38M	$61.03M	$66.75M	$66.28M	$65.05M	$58.04M	$78.09M	$79.39M	$69.37M	$66.37M	$50.77M	$48.57M	$42.85M	$36.27M	$35.98M	$34.76M	$28.37M	$25.23M	$23.74M	$22.97M	$19.11M	$16.72M	$15.74M	$15.00M	$8.80M	$13.72M	$11.74M	$9.45M
# Analysts	1	1	1	1	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.17%	1.27%	1.13%	1.12%	1.03%	1.06%	1.23%	1.06%	1.05%	1.02%	1.19%	1.36%	1.10%	1.01%	1.45%	1.27%	1.50%	1.56%

Castle Biosciences's average Quarter revenue forecast for Mar 24 based on 4 analysts is $66.55M, with a low forecast of $66.37M, and a high forecast of $66.72M. CSTL's average Quarter revenue forecast represents a 0.65% increase compared to the company's last Quarter revenue of $66.12M (Dec 23).

Castle Biosciences EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$3.12M	$-9.64M	$-21.16M	$-26.29M	$-18.64M	$-17.47M	$-21.37M	$-22.34M	$-13.71M	$-10.70M	$-8.15M	$-4.05M	$-4.25M	$-3.76M	$-505.00K	$1.43M	$2.99M	$7.03M
Avg Forecast	$-14.34M	$-14.31M	$-14.09M	$-12.40M	$-13.56M	$-13.46M	$-13.21M	$-11.79M	$-15.86M	$-15.73M	$-13.66M	$-17.13M	$-11.08M	$-9.57M	$-8.70M	$-15.57M	$-19.92M	$-8.30M	$-6.78M	$-14.16M	$-5.67M	$-5.49M	$-4.57M	$-5.10M	$-3.76M	$-3.58M	$-2.10M	$2.82M	$-2.80M	$-2.26M
High Forecast	$-13.90M	$-13.87M	$-13.66M	$-12.02M	$-13.15M	$-13.05M	$-12.81M	$-11.43M	$-15.38M	$-15.63M	$-13.66M	$-13.70M	$-10.00M	$-9.57M	$-8.44M	$-12.46M	$-15.94M	$-8.30M	$-6.78M	$-11.32M	$-5.67M	$-5.49M	$-4.57M	$-4.08M	$-3.76M	$-3.58M	$-2.10M	$3.39M	$-2.80M	$-2.26M
Low Forecast	$-14.92M	$-14.88M	$-14.66M	$-12.90M	$-14.10M	$-14.01M	$-13.75M	$-12.26M	$-16.50M	$-15.82M	$-13.66M	$-20.55M	$-12.17M	$-9.57M	$-9.05M	$-18.69M	$-23.90M	$-8.30M	$-6.78M	$-16.99M	$-5.67M	$-5.49M	$-4.57M	$-6.12M	$-3.76M	$-3.58M	$-2.10M	$2.26M	$-2.80M	$-2.26M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.28%	1.01%	2.43%	1.69%	0.94%	2.10%	3.15%	1.58%	2.42%	1.95%	1.79%	0.79%	1.13%	1.05%	0.24%	0.51%	-1.07%	-3.11%

4 analysts predict CSTL's average Quarter EBITDA for Mar 24 to be $-17.13M, with a high of $-13.70M and a low of $-20.55M. This is -649.17% lower than Castle Biosciences's previous annual EBITDA (Dec 23) of $3.12M.

Castle Biosciences Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-2.58M	$-6.91M	$-18.78M	$-29.20M	$-20.62M	$-18.81M	$-1.65M	$-24.62M	$-6.43M	$-11.79M	$-8.79M	$-4.28M	$-4.89M	$-4.59M	$-1.38M	$570.00K	$2.05M	$5.85M
Avg Forecast	$-9.11M	$-10.00M	$-10.58M	$-19.11M	$-13.76M	$-13.85M	$-15.43M	$-20.91M	$424.67K	$-118.10K	$-7.90M	$-18.88M	$-16.53M	$-22.46M	$-26.90M	$-17.17M	$-9.35M	$-25.31M	$-21.89M	$-15.61M	$-13.52M	$-11.64M	$-9.55M	$-5.40M	$-3.50M	$-3.29M	$-11.42M	$1.13M	$-4.53M	$11.41M
High Forecast	$-8.75M	$-9.60M	$-10.16M	$-18.35M	$-13.21M	$-13.30M	$-14.82M	$-20.08M	$446.84K	$-113.42K	$-7.59M	$-15.11M	$-14.17M	$-21.57M	$-25.84M	$-13.73M	$-7.48M	$-25.31M	$-21.89M	$-12.48M	$-13.52M	$-11.64M	$-9.55M	$-4.32M	$-3.50M	$-3.29M	$-11.42M	$1.35M	$-4.53M	$13.69M
Low Forecast	$-9.59M	$-10.52M	$-11.14M	$-20.11M	$-14.47M	$-14.57M	$-16.23M	$-22.00M	$407.83K	$-124.27K	$-8.31M	$-22.66M	$-18.70M	$-23.64M	$-28.31M	$-20.60M	$-11.21M	$-25.31M	$-21.89M	$-18.73M	$-13.52M	$-11.64M	$-9.55M	$-6.48M	$-3.50M	$-3.29M	$-11.42M	$902.88K	$-4.53M	$9.12M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.16%	0.31%	0.70%	1.70%	2.21%	0.74%	0.08%	1.58%	0.48%	1.01%	0.92%	0.79%	1.40%	1.39%	0.12%	0.51%	-0.45%	0.51%

Castle Biosciences's average Quarter net income forecast for Jun 20 is $-11.42M, with a range of $-11.42M to $-11.42M. CSTL's average Quarter net income forecast represents a -2104.10% decrease compared to the company's last Quarter net income of $570.00K (Mar 20).

Castle Biosciences SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$44.09M	$44.62M	$44.68M	$46.76M	$38.43M	$36.63M	$37.50M	$30.45M	$25.16M	$22.59M	$20.82M	$18.16M	$13.08M	$13.59M	$8.51M	$11.08M	$9.85M	$7.12M
Avg Forecast	$60.13M	$60.00M	$59.09M	$51.98M	$56.86M	$56.45M	$55.41M	$49.43M	$66.51M	$65.94M	$57.28M	$23.35M	$46.47M	$40.11M	$36.49M	$21.23M	$36.57M	$28.66M	$23.39M	$19.30M	$19.57M	$18.94M	$15.76M	$13.79M	$12.98M	$12.37M	$7.25M	$11.31M	$9.68M	$7.80M
High Forecast	$62.55M	$62.41M	$61.46M	$54.07M	$59.14M	$58.72M	$57.63M	$51.42M	$69.18M	$66.32M	$57.28M	$28.03M	$51.01M	$40.11M	$37.96M	$25.48M	$43.88M	$28.66M	$23.39M	$23.16M	$19.57M	$18.94M	$15.76M	$13.79M	$12.98M	$12.37M	$7.25M	$11.31M	$9.68M	$7.80M
Low Forecast	$58.30M	$58.17M	$57.29M	$50.40M	$55.12M	$54.73M	$53.72M	$47.92M	$64.48M	$65.55M	$57.28M	$18.68M	$41.93M	$40.11M	$35.38M	$16.99M	$29.25M	$28.66M	$23.39M	$15.44M	$19.57M	$18.94M	$15.76M	$13.79M	$12.98M	$12.37M	$7.25M	$11.31M	$9.68M	$7.80M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.95%	1.11%	1.22%	2.20%	1.05%	1.28%	1.60%	1.58%	1.29%	1.19%	1.32%	1.32%	1.01%	1.10%	1.17%	0.98%	1.02%	0.91%

Castle Biosciences's average Quarter SG&A projection for Mar 24 is $23.35M, based on 4 Wall Street analysts, with a range of $18.68M to $28.03M. The forecast indicates a -47.03% fall compared to CSTL last annual SG&A of $44.09M (Dec 23).

Castle Biosciences EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	4	2	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	4	4	4	3	3
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.10	$-0.26	$-0.70	$-1.10	$-0.78	$-0.71	$-0.06	$-0.97	$-0.25	$-0.47	$-0.35	$-0.17	$-0.23	$-0.23	$-0.08	$0.03	$0.12	$0.43
Avg Forecast	$-0.31	$-0.34	$-0.36	$-0.65	$-0.47	$-0.47	$-0.52	$-0.71	$0.01	$-0.00	$-0.27	$-0.33	$-0.56	$-0.76	$-0.92	$-0.89	$-0.84	$-0.88	$-0.76	$-0.71	$-0.47	$-0.41	$-0.33	$-0.23	$-0.12	$-0.11	$-0.40	$-0.15	$-0.16	$-0.30
High Forecast	$-0.30	$-0.33	$-0.35	$-0.62	$-0.45	$-0.45	$-0.50	$-0.68	$0.02	$-0.00	$-0.26	$-0.32	$-0.48	$-0.73	$-0.88	$-0.86	$-0.80	$-0.88	$-0.76	$-0.71	$-0.47	$-0.41	$-0.33	$-0.23	$-0.12	$-0.11	$-0.40	$-0.15	$-0.16	$-0.30
Low Forecast	$-0.33	$-0.36	$-0.38	$-0.68	$-0.49	$-0.50	$-0.55	$-0.75	$0.01	$-0.00	$-0.28	$-0.35	$-0.64	$-0.80	$-0.96	$-0.94	$-0.88	$-0.88	$-0.76	$-0.71	$-0.47	$-0.41	$-0.33	$-0.23	$-0.12	$-0.11	$-0.40	$-0.15	$-0.16	$-0.30
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.17%	0.34%	0.76%	1.24%	0.93%	0.81%	0.08%	1.37%	0.53%	1.16%	1.05%	0.73%	1.89%	2.01%	0.20%	-0.20%	-0.76%	-1.41%

According to 4 Wall Street analysts, Castle Biosciences's projected average Quarter EPS for Jun 20 is $-0.40, with a low estimate of $-0.40 and a high estimate of $-0.40. This represents a -1425.00% decrease compared to CSTL previous annual EPS of $0.03 (Mar 20).

Castle Biosciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
LMDX	LumiraDx	$0.02	$1.50	7400.00%	Buy
STIM	Neuronetics	$0.78	$8.00	925.64%	Buy
GTH	Genetron	$4.03	$10.00	148.14%	-
BDSX	Biodesix	$1.26	$3.00	138.10%	Buy
PSNL	Personalis	$3.59	$7.75	115.88%	Hold
GH	Guardant Health	$28.96	$57.27	97.76%	Buy
XGN	Exagen	$3.00	$5.00	66.67%	Buy
CSTL	Castle Biosciences	$27.90	$40.50	45.16%	Buy
CDNA	CareDx	$21.56	$29.75	37.99%	Buy
TWST	Twist Bioscience	$41.43	$42.40	2.34%	Buy
OLK	Olink AB (publ)	$26.08	$21.50	-17.56%	Hold
NTRA	Natera	$153.42	$120.92	-21.18%	Buy

CSTL Forecast FAQ

Is Castle Biosciences a good buy?

Yes, according to 4 Wall Street analysts, Castle Biosciences (CSTL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of CSTL's total ratings.

What is CSTL's price target?

Castle Biosciences (CSTL) average price target is $40.5 with a range of $36 to $45, implying a 45.16% from its last price of $27.9. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Castle Biosciences stock go up soon?

According to Wall Street analysts' prediction for CSTL stock, the company can go up by 45.16% (from the last price of $27.9 to the average price target of $40.5), up by 61.29% based on the highest stock price target, and up by 29.03% based on the lowest stock price target.

Can Castle Biosciences stock reach $40?

CSTL's average twelve months analyst stock price target of $40.5 supports the claim that Castle Biosciences can reach $40 in the near future.

What is Castle Biosciences's current price target trend?

4 Wall Street analysts forecast a $40.5 price target for Castle Biosciences (CSTL) this month, up 45.16% from its last price of $27.9. Compared to the last 3 and 12 months, the average price target increased by 44.80% and increased by 41.58%, respectively.

What are Castle Biosciences's analysts' financial forecasts?

Castle Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $264.19M (high $274.8M, low $256.13M), average EBITDA is $-52.029M (high $-50.442M, low $-54.119M), average net income is $-63.937M (high $-61.402M, low $-67.276M), average SG&A $218.15M (high $226.91M, low $211.5M), and average EPS is $-2.175 (high $-2.088, low $-2.288). CSTL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $279.99M (high $291.24M, low $271.45M), average EBITDA is $-55.141M (high $-53.459M, low $-57.356M), average net income is $-48.806M (high $-46.87M, low $-51.354M), average SG&A $231.2M (high $240.49M, low $224.15M), and average EPS is $-1.66 (high $-1.594, low $-1.747).

Did the CSTL's actual financial results beat the analysts' financial forecasts?

Based on Castle Biosciences's last annual report (Dec 2023), the company's revenue was $219.79M, beating the average analysts forecast of $186.45M by 17.88%. Apple's EBITDA was $10.62M, missing the average prediction of $-44.924M by -123.65%. The company's net income was $-57.466M, missing the average estimation of $-83.069M by -30.82%. Apple's SG&A was $180.15M, beating the average forecast of $144.3M by 24.84%. Lastly, the company's EPS was $-2.14, missing the average prediction of $-3.132 by -31.67%. In terms of the last quarterly report (Dec 2023), Castle Biosciences's revenue was $66.12M, beating the average analysts' forecast of $56.28M by 17.49%. The company's EBITDA was $3.12M, missing the average prediction of $-11.083M by -128.14%. Castle Biosciences's net income was $-2.58M, missing the average estimation of $-16.534M by -84.40%. The company's SG&A was $44.09M, missing the average forecast of $46.47M by -5.12%. Lastly, the company's EPS was $-0.0954, missing the average prediction of $-0.562 by -83.04%